New combo therapy aims to boost ovarian cancer surgery success
NCT ID NCT07432594
First seen Feb 27, 2026 · Last updated May 14, 2026 · Updated 9 times
Summary
This study tests whether adding an immunotherapy drug (Aitua Combination Antibody) to standard chemotherapy before surgery helps remove more advanced ovarian cancer. About 82 people with stage IIIC-IV high-grade serous ovarian cancer who cannot have optimal initial surgery will be randomly assigned to get chemo with or without the immunotherapy. The main goal is to see if more participants have complete tumor removal during surgery.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY PERITONEAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.